 and identiÔ¨Åed
after TEVAR for TAA generally ranges from 3.2% to
6.2%,131 and it may be lethal in one third of these
cases.132 However, this range may vary according to the
indication for TEVAR. A meta-analysis of the Cooksponsored multicenter trials demonstrated even lower
rates in certain populations of patients, with a 30-day
stroke rate of 0% in the 5